FDA Inspection 1193294 — Blueprint Medicines Corporation
The FDA completed an inspection of Blueprint Medicines Corporation on November 18, 2022 in Cambridge, MA. The inspection was classified NAI (No Action Indicated — no objectionable conditions were found). Product area: Drugs.
Inspection Details
- Classification
- No Action Indicated (NAI) (NAI)
- End Date
- November 18, 2022
- Fiscal Year
- 2023
- Product Type
- Drugs
- Project Area
- Bioresearch Monitoring
- Location
- Cambridge, MA (United States)
Additional Details
Postmarket Adverse Drug Experience (PADE)